Impact of intestinal metabolism on drug development.
Mizuma
Takashi
T
mizuma@ps.toyaku.ac.jp
D000284:Administration, Oral; D015239:Arylsulfotransferase; D001682:Biological Availability; D051544:Cytochrome P-450 CYP3A; D016503:Drug Delivery Systems; D055808:Drug Discovery; D014453:Glucuronosyltransferase; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000201:enzymology; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D011355:Prodrugs; D015238:Sulfotransferases
D004364:Pharmaceutical Preparations; D011355:Prodrugs; D051544:Cytochrome P-450 CYP3A; C476725:bilirubin uridine-diphosphoglucuronosyl transferase 1A10; D014453:Glucuronosyltransferase; C454320:UDP-glucuronosyltransferase, UGT1A8; D015238:Sulfotransferases; D015239:Arylsulfotransferase; C403170:monoamine-sulfating phenol sulfotransferase